# Supplementary Documents of Consolidated Financial Results for the First Quarter of FY2026 (from April 1, 2026 to March 31, 2027)

August 4, 2026

Securities code：4886 (TSE)

ASKA Pharmaceutical Holdings Co., Ltd.

Note:This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

# Highlight



## FY2026 1Q (Consolidated)

| | |
|---|---|
| **Net sales** | ✓ **17.3 billion yen, decreased 1.5% YOY**<br>Decrease due to NHI drug price revisions in the Pharmaceuticals business and the impact of the Overseas business and other factors. |
| **Cost of sales** | ✓ **9.2 billion yen, COS ratio increased 2.4 percentage points YOY**<br>Increase due to higher raw material prices and other factors |
| **SG&A expenses** | ✓ **7.3 billion yen, SGA ratio increased 1.8 percentage points YOY**<br>Increase due to higher R&D expenses associated with the progress of clinical trials |
| **Operating profit** | ✓ **0.7 billion yen, decreased 51.4% YOY**<br>Decrease in profit due to higher cost of sales and increased R&D expenses |

## FY2026 (Consolidated)

*** Unchanged from the initial forecast**

| | |
|---|---|
| **Performance forecast** | ✓ **Net sales 73.0 billion yen, up 2.6% YOY**<br>✓ **Operating profit 6.2 billion yen, up 6.3% YOY** |

# Statements of Income (Consolidated)



| (Millions of yen) | FY2025 Apr - Jun Actual | FY2026 Apr - Jun Actual | Actual +/- | Growth +/- |
|---|---|---|---|---|
| **Net sales** | 17,641 | 17,384 | -257 | -1.5% |
| **Operating profit** | 1,464 | 711 | -753 | -51.4% |
| **Ordinary profit** | 1,594 | 817 | -776 | -48.7% |
| **Profit attributable to owners of parent** | 1,255 | 533 | -722 | -57.5% |

- ✓ Revenue decreased due to the continued impact of NHI drug price revisions in the prescription pharmaceuticals business, as well as difficulties in procuring APIs for key products in the overseas business caused by the deteriorating situation in the Middle East.
- ✓ On the profit front, operating profit decreased 51.4% year on year, ordinary profit decreased 48.7%, and profit attributable to owners of parent decreased 57.5%, mainly due to an increase in cost of sales resulting from higher raw material prices, as well as an increase in research and development expenses associated with the progress of clinical trials.

# Consolidated Sales and Proft/Loss by Business Segment

(Millions of yen)

| | | FY2025 Apr - Jun Actual | FY2026 Apr - Jun Actual | Breakdown | Actual +/- | Growth +/- |
|---|---|---|---|---|---|---|
| **Pharmaceutical business** | **Sales** | **14,515** | **14,484** | **83.3%** | **-31** | **-0.2%** |
| | **Profit** | 1,698 | 1,132 | — | -565 | -33.3% |
| **Animal health business** | **Sales** | **1,841** | **1,952** | **11.2%** | **111** | **6.1%** |
| | **Profit** | 128 | 44 | — | -84 | -65.4% |
| **Overseas business** | **Sales** | **1,226** | **908** | **5.2%** | **-317** | **-25.9%** |
| | **Profit** | 58 | -35 | — | -94 | — |
| **Other business (clinical testing and medical devices)** | **Sales** | **58** | **38** | **0.2%** | **-19** | **-33.4%** |
| | **Profit** | -2 | -8 | — | -6 | — |
| **Total Sales** | | **17,641** | **17,384** | **100.0%** | **-257** | **-1.5%** |

- ✓ The prescription pharmaceuticals business recorded a slight year-on-year decrease in revenue due to the impact of NHI drug price revisions and other factors. While THYRADIN and RIFXIMA in the internal medicine field, as well as LEUPRORELIN in the urology field, continued to perform steadily, sales of DroEthi and other products in the gynecology field declined.
- ✓ The animal health business recorded a 6.1% year-on-year increase in revenue, driven by growth in feed additives and other products. On the other hand, profit declined due to higher procurement costs for feed additives and other factors.
- ✓ Sales and profit in the overseas business decreased due to difficulties in procuring active pharmaceutical ingredients for its mainstay products and other factors.

ASKA Pharmaceutical Holdings Co., Ltd.

# Sales of Main Products (Pharmaceutical Business)

(Millions of yen)

| Area | Category | Products (generic name) | FY2025 Apr - Jun | FY2026 Apr - Jun | | FY2026 Apr - Mar | | Reference | Notes |
|---|---|---|---|---|---|---|---|---|---|
| | | | Actual | Actual | YOY | Forecast | YOY | Initial Forecast | |
| Internal Medicine | Brand-name | THYRADIN (levothyroxine) | 2,125 | 2,257 | 6.2% | 9,082 | 3.5% | 9,082 | Higher NHI drug prices, and increased sales volume |
| Internal Medicine | Brand-name | RIFXIMA (rifaximin) | 1,902 | 1,982 | 4.2% | 8,023 | 1.8% | 8,023 | Progress generally in line with expectations |
| Internal Medicine | AG | CANDESARTAN[1] (candesartan) | 2,074 | 1,814 | -12.5% | 7,213 | -8.5% | 7,213 | Despite lower NHI drug prices, sales volume remained largely unchanged |
| Internal Medicine | Brand-name | MERCAZOLE (thiamazole) | 406 | 434 | 6.7% | 1,745 | 5.5% | 1,745 | Higher NHI drug prices, with sales volume remaining largely unchanged |
| Obstetrics and Gynecology | Brand-name | RELUMINA (relugolix) | 2,768 | 2,776 | 0.3% | 11,340 | 1.5% | 11,340 | Despite lower NHI drug prices, sales volume increased |
| Obstetrics and Gynecology | Generic | DroEthi (drospirenone/ethinylestradiol) | 2,022 | 1,946 | -3.8% | 7,678 | -7.6% | 7,678 | Despite lower NHI drug prices, sales volume increased |
| Obstetrics and Gynecology | AG | FREWELL (norethisterone/ethinylestradiol) | 747 | 636 | -14.8% | 2,586 | -13.0% | 2,586 | Despite lower NHI drug prices, sales volume remained largely unchanged |
| Obstetrics and Gynecology | Brand-name | LUTEUM (progesterone) | 538 | 553 | 2.9% | 2,197 | -3.2% | 2,197 | Performance remained solid as the impact of competing products subsided |
| Obstetrics and Gynecology | Brand-name | Slinda (drospirenone) | 74 | 241 | 224.9% | 1,019 | 159.9% | 1,019 | Market share expanded as expected |
| Urol-ogy | Generic | LEUPRORELIN[2] (leuprorelin) | 962 | 1,064 | 10.5% | 5,596 | 44.2% | 5,596 | Focused on promoting the switch from the originator to our generic product. |

[1] Including fixed dose combination

[2] 1.88mg formulation is only for gynecological indications but combined with 3.75mg formulation and SR agent (11.25mg formulation launched in December 2025)

# Sales by Major Business Field (Animal Health Business)

(Millions of yen)

| Business field | FY2025 Apr - Jun | FY2026 Apr - Jun | | FY2026 Apr - Mar | |
|---|---|---|---|---|---|
| | Actual | Actual | YOY | Forecast | YOY |
| Feed additives<br>Mixed feed<br>Feed materials | 1,143 | 1,307 | 14.4% | 4,469 | -1.0% |
| Veterinary pharmaceuticals<br>(livestock and fisheries + CA*) | 674 | 636 | -5.7% | 2,827 | 7.1% |

✓ While sales in veterinary pharmaceuticals decreased 5.7% year on year, sales in the feed additives field remained solid increased 14.4% year on year.

* Companion Animal

# Sales Ratio / Sales Proportion of Brand-name Drugs

## Sales Ratio (1Q FY2026)




The total may not add up to 100 because the figures are rounded to the second decimal place.

## Sales Proportion of Brand-name Drugs




The product mix improved due to growth in Slinda, RIFXIMA, RELUMINA and THYRADIN, resulting in a 2.5 percentage point increase in the ratio of brand-name drugs to sales.

# R&D Status

## Trend of R&D expenses

(Millions of yen)




## As of August 4, 2026

| Development code (Generic name) / Indication | Phase |
|---|---|
| AKP-022 (Relugolix combination tablet)<br>Uterine fibroids | Ph III ongoing |
| AKP-022 (Relugolix combination tablet)<br>Endometriosis | Ph III ongoing |
| LPRI-CF113 (drospirenone)<br>Dysmenorrhea | Ph I/II ongoing |
| AKP-SMD106 (Digital therapeutics app[1])<br>Premenstrual syndrome/premenstrual dysphoric disorder | Specified clinical trial[2] ongoing |
| AKP-009 (Iudaterone acetate)<br>Polycystic ovary syndrome | Preparing clinical trials |
| MCN-009 (Digital therapeutics app[1])<br>Irritable bowel syndrome | Confirmatory clinical trial[3] ongoing |
| AKP-009 (Iudaterone acetate)<br>Benign prostatic hyperplasia | Ph II ongoing |
| AKP-021 (mPGES-1 inhibitor agent) | Ph I ongoing |
| AKP-017 (intranasal teststerone) | Preparing clinical trials |

1. The regulatory nonproprietary name has not been determined as it is planned to be newly established
2. Equivalent to PhII for ethical pharmaceutical drugs; co-developed with SUSMED, Inc.
3. Equivalent to PhIII for ethical pharmaceutical drugs; co-developed with MICIN, Inc.